Old West Investment Management LLC Takes Position in Ralliant Corporation $RAL

Old West Investment Management LLC purchased a new position in shares of Ralliant Corporation (NYSE:RAL) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 29,903 shares of the company’s stock, valued at approximately $2,202,000.

Other hedge funds also recently modified their holdings of the company. Global Retirement Partners LLC purchased a new position in Ralliant in the second quarter valued at approximately $35,000. Danske Bank A S purchased a new stake in Ralliant in the fourth quarter worth $25,000. Allworth Financial LP increased its position in Ralliant by 134.4% in the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after buying an additional 293 shares during the last quarter. Palisade Asset Management LLC bought a new stake in shares of Ralliant in the third quarter valued at $26,000. Finally, Versant Capital Management Inc raised its stake in shares of Ralliant by 230.1% in the second quarter. Versant Capital Management Inc now owns 604 shares of the company’s stock valued at $44,000 after buying an additional 421 shares during the period.

Analysts Set New Price Targets

A number of research analysts have recently commented on RAL shares. Truist Financial reaffirmed a “buy” rating and set a $82.00 price target (up from $68.00) on shares of Ralliant in a research report on Friday, July 31st. TD Cowen lifted their price objective on Ralliant from $70.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Vertical Research cut Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price objective on the stock. in a research note on Wednesday, May 27th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ralliant in a report on Friday, July 31st. Finally, Citigroup increased their target price on shares of Ralliant from $81.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Ralliant currently has an average rating of “Moderate Buy” and an average target price of $75.70.

Ralliant Trading Up 0.1%

Shares of RAL stock opened at $72.34 on Monday. The stock has a market capitalization of $8.00 billion, a price-to-earnings ratio of -6.67, a PEG ratio of 2.69 and a beta of 1.61. The company’s fifty day simple moving average is $68.60 and its two-hundred day simple moving average is $55.45. Ralliant Corporation has a 1 year low of $37.27 and a 1 year high of $75.41. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.52 and a quick ratio of 1.00.

Ralliant (NYSE:RAL) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.05. The firm had revenue of $567.80 million during the quarter. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. As a group, analysts anticipate that Ralliant Corporation will post 2.87 earnings per share for the current year.

Ralliant Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Tuesday, September 8th will be paid a $0.05 dividend. The ex-dividend date is Tuesday, September 8th. This represents a $0.20 annualized dividend and a yield of 0.3%. Ralliant’s dividend payout ratio (DPR) is currently -1.84%.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.